Pregled bibliografske jedinice broj: 1014433
The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis
The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis // Urologic oncologic-seminars and original investigations, 37 (2019), 9; 578e, 10 doi:10.1016/j.urolonc.2019.03.007 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1014433 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis
Autori
Knezović Florijan, Marijana ; Ozretić, Petar ; Bujak, Maro ; Pezzè, Laura ; Ciribilli, Yari ; Kaštelan, Željko ; Slade, Neda ; Hudolin, Tvrtko
Izvornik
Urologic oncologic-seminars and original investigations (1078-1439) 37
(2019), 9;
578e, 10
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
p53 ; p53 isoforms ; renal cell cancer ; p53 mutation
Sažetak
Objectives: To analyze p53 mutations and gene expression of p53, ∆40p53, and ∆133p53 isoforms in renal cell cancer (RCC) tissues and normal adjacent tissue (NAT) and to associate them to clinical features and outcome. Patients and methods: Forty-one randomly selected patients, with primary, previously untreated RCC, with complete clinicopathohistological data were analyzed. NAT samples were available for 37 cases. Expression of p53, ∆40p53 and ∆133p53 was determined using RT-qPCR. A functional yeast-based assay was performed to analyze p53 mutations. Results: More than half (56.1%) of patients harbored functional p53 mutations, and they were significantly younger than those with wild type (WT) p53 (P = 0.032). Expression of p53, ∆40p53, and ∆133p53 was upregulated in mutant (MT) p53 RCC compared to WT p53 RCC tissues. However, there was no difference in expression of these isoforms between MT p53 RCC tissues and NAT. Expression of ∆133p53 was significantly downregulated in WT p53 tissues compared to NAT (P = 0.006). Patients that harbored functional p53 mutation had better overall survival (hazard ratio 4.32, 95% confidence interval 1.46–18.82, P = 0.006). Multivariate analysis demonstrated that tumor stage and p53 mutation might be used as independent prognostic marker for overall survival in RCC patients. Conclusions: Our findings support the specific events in the carcinogenesis of RCC. p53 isoforms can be differentially expressed depending on p53 mutational status.
Izvorni jezik
Engleski
Znanstvena područja
Biologija, Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
HRZZ-IP-2013-11-1615 - Otkrivanje novih proteinskih interakcija kao podloga za nove pristupe liječenju melanoma čovjeka (ProNetMel) (Slade, Neda, HRZZ - 2013-11) ( CroRIS)
Ustanove:
Institut "Ruđer Bošković", Zagreb,
Medicinski fakultet, Zagreb,
KBC "Sestre Milosrdnice",
Klinički bolnički centar Zagreb
Profili:
Tvrtko Hudolin
(autor)
Željko Kaštelan
(autor)
Neda Slade
(autor)
Maro Bujak
(autor)
Petar Ozretić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE